Cellusion participating in the 2023 BIO International Convention
CEO Dr. Hatou will present our business progress

Cellusion Inc. (CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) will participate in the 2023 BIO International Convention to be held in Boston, MA, USA, from June 5 to 8, 2023. On June 6 at 3:15 (local time), our CEO, Dr. Hatou is scheduled to give a company presentation on the progress of the business in Room 104A.

This convention is one of the world’s largest business matching events in the biotechnology field (regenerative medicine, drug discovery, drug discovery support, etc.) hosted by the Biotechnology Innovation Organization. It attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.

By expanding the network through participation in international events, Cellusion will promote the global development of its lead program, the development of corneal endothelial regenerative medicine using iPS cells for the treatment of bullous keratopathy.

2023 BIO International Convention Official Website

[About Cellusion]
Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi endothelial cells. Cellusion’s mission is “Regenerating Human Potential,” and its vision is “More Freedom and More Smiles to the World.”

Company: Cellusion Inc.
CEO: Shin Hatou, M.D., Ph.D.
Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN
Founded: January 2015
URL: https://cellusion.jp/en/

For further information: please ask us through the contact form on our website.